Endonovo Therapeutics Signs Definitive Asset Purchase Agreement to Acquire A Highly Profitable Texas Concrete Construction Company

Rhea-AI Summary

Endonovo Therapeutics has signed a definitive purchase agreement to acquire all assets and operations of Western Star Concrete, a profitable Texas concrete construction company. This acquisition, expected to close by December 15, 2022, is projected to significantly enhance Endonovo's position in the specialty concrete sector. Western Star generates annual operating profits of $6.3 million, with anticipated revenues between $30 million and $60 million. The strategic acquisition will facilitate a projected 15% to 20% annual growth rate, expanding Endonovo’s footprint in the Southeast U.S.

Positive

• Acquisition of Western Star Concrete is expected to significantly enhance Endonovo's position in the specialty concrete sector.
• Western Star generates $6.3 million in annual operating profits, indicating a strong financial foundation.
• Projected revenues from Western Star are estimated between $30 million and $60 million.
• Acquisition is anticipated to facilitate a Compound Annual Growth Rate (CAGR) of 15% to 20% annually.

Negative

• None.

Los Angeles, CA., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) and Western Star Concrete LLC, a highly profitable Texas concrete construction company located in the greater Dallas region, today announced the signing of a definitive purchase agreement for Endonovo to acquire all of Western Star’s assets and business operations.

The Agreement is a unique opportunity to greatly enhance Western Star’s position as a regional leader in the specialty concrete construction sector with multiple expansion opportunities generally throughout the Southeast region of the US. Presently, Western Star business generates revenue with net annual operating profits of $6.3 million.

“The acquisition of the Western Star assets and the opportunities to expand into other geographic regions in Texas present significant opportunities to significantly increase company net cash flows. The current profitability and future demonstrable growth provides a great value for Endonovo and our shareholders”, CEO Alan Collier said in making the announcement. “This opportunity will be accretive for Endonovo’s valuation from year one. There will be significant potential for synergies estimated, under normal operating conditions and generate between $30 million and $60 million in revenues per year according to three-year lookback financial reporting,” he said.

Collier also pointed out: “The new Endonovo construction entity formed will aim to continue to generate a Compound Annual Growth Rate (CAGR) of an estimated 15% to 20% annually. Ongoing business will be structured and expanded through the already successful Western Star management team that, as an example produced 52% growth from 2020 to 2021. Western Star financial performance has sustained a 15% to 20% CAGR over a three-year financial lookback in the specialized concrete construction sector. Our vision for Western Star’s business expansion would have broad geographical reach with present marketing plans to expand into multiple Texas cities in the next few years.”

The acquisition of Western Star allows Endonovo to expand and solidify its mergers and acquisition division, directed by Endonovo’s Director of Corporate Development, Garry Michael Kann. The current corporate strategy of the mergers and acquisition division is to expand company assets through the Build Up of complementary, highly profitable specialty construction businesses with complimentary businesses throughout the U.S.

Western Star has established an excellent reputation in the residential building sector in one of the nation’s top housing markets for 2022 as written by realtor.com. Specialized construction is an extremely strong growth potential market. For example, Statista.com forecast the annual growth rate of 3.89% is expected CAGR 2022-2025). U.S. specialized construction is also a resilient sector dominated by long-term contracts with recurring revenue streams and a strong EBITDA-to-cash conversion rate, which will help underpin Endonovo’s future profits.

Closing of the transaction is estimated to be by December 15, 2022. The proposed acquisition has been approved by the both the Board of Directors of Endonovo and Western Star’s owner.

About Endonovo Therapeutics, Inc.

Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals^® therapeutic devices for pain relief, general wellness and wound curatives. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals^® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical^® therapeutic device, SofPulse^®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema. It also has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals^® therapeutic devices addresses chronic kidney disease, liver disease, non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's noninvasive, wearable Electroceuticals^® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:
Endonovo Therapeutics, Inc.
Steve Barnes
(800) 701-1223 Ext. 108
sbarnes@endonovo.com
www.endonovo.com

Media Contact:
Gregory A. McAndrews
Greg McAndrews & Associates
(310) 804-7037
greg@gregmcandrews.com

XXX

FAQ

What is the significance of Endonovo's acquisition of Western Star Concrete?

The acquisition enhances Endonovo's position in the specialty concrete sector, providing opportunities for growth and a strong financial performance.

When is the closing date for the Endonovo and Western Star acquisition?

The transaction is expected to close by December 15, 2022.

What are the expected revenue projections from the Western Star acquisition?

Endonovo anticipates revenues between $30 million and $60 million from the acquisition.

What growth rate is expected from Western Star's operations for Endonovo?

The new entity aims for a Compound Annual Growth Rate (CAGR) of 15% to 20% annually.